U.S. markets closed

Veru Inc. (VERU)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
9.01-0.23 (-2.49%)
At close: 4:00PM EDT

9.26 +0.25 (2.77%)
After hours: 7:58PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Outside Bar (Bullish)

Outside Bar (Bullish)

Previous Close9.24
Open9.46
Bid9.01 x 900
Ask9.32 x 800
Day's Range8.95 - 9.48
52 Week Range2.30 - 24.57
Volume745,822
Avg. Volume3,748,537
Market Cap706.055M
Beta (5Y Monthly)0.74
PE Ratio (TTM)391.74
EPS (TTM)0.02
Earnings DateFeb 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateApr 28, 2014
1y Target Est23.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Veru Announces Presentation of Phase 2 Study of Enobosarm -- a Selective Androgen Receptor Targeting Agent in Metastatic AR+ER+HER2- Breast Cancer at 2021 ESMO Breast Cancer Congress
    GlobeNewswire

    Veru Announces Presentation of Phase 2 Study of Enobosarm -- a Selective Androgen Receptor Targeting Agent in Metastatic AR+ER+HER2- Breast Cancer at 2021 ESMO Breast Cancer Congress

    MIAMI, April 21, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that clinical results from the Phase 2 clinical study of enobosarm, a selective androgen receptor targeting agonist, in heavily pretreated women with AR+ER+HER2- advanced breast cancer including further efficacy data and an analysis of patients who have failed both estrogen blocking agents and CDK 4/6 inhibitors, has been accepted for a poster presentation at the European Society for Medical Oncology (ESMO) Breast Cancer Virtual Congress 2021 to be held May 05-08, 2021. Enobosarm is an oral, first-in-class, selective androgen receptor targeting agonist that activates the androgen receptor, a tumor suppressor, in AR+ER+HER2- metastatic breast cancer. The planned Phase 3 ARTEST study will evaluate enobosarm monotherapy versus an active control (exemestane or SERM) for the treatment of metastatic AR+ER+HER2- breast cancer patients whose disease has progressed after treatment with a nonsteroidal aromatase inhibitor (anastrozole or letrozole), fulvestrant, and a CDK 4/6 inhibitor and the study is anticipated to commence in Q2 2021. Presentation details: Abstract Title: Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, in patients with metastatic AR+ER+ breast cancer resistant to estrogen receptor targeted agents and CDK 4/6 inhibitor in a Phase 2 clinical study Presenter: Carlo Palmieri, BSc, MB BS, PhD, FRC, Professor of Translational Oncology & Medical Oncologist, University of LiverpoolAbstract Number: 568 Additional information on the meeting can be found on the ESMO website https://www.esmo.org/meetings/esmo-breast-2021-virtual “With the recent validation of the androgen receptor as a tumor suppressor and a therapeutic target in AR+ER+HER2- breast cancer as well as the positive proof of concept efficacy and safety results in the Phase 2 clinical study, we remain very excited about advancing the clinical development of enobosarm into a Phase 3 ARTEST registration trial and its potential role in the targeted treatment refractory AR+ER+HER2- advanced breast cancer,” said Dr. Mitchell Steiner, Chairman, President and CEO of Veru Inc. About Veru Inc.Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer. Veru’s prostate cancer pipeline includes: VERU-111, an oral, first-in-class, targeted cytoskeleton disruptor, is expected to commence in Q2 2021 a Phase 3 VERACITY clinical trial in approximately 245 men for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer. VERU-100, a novel, proprietary GnRH antagonist peptide long acting 3-month subcutaneous injection formulation for androgen deprivation therapy, will start the planned Phase 2 clinical study in Q2 2021 and the Phase 3 clinical study in Q4 2021 to treat hormone sensitive advanced prostate cancer. Veru’s breast cancer pipeline includes: enobosarm, an oral, first-in-class, new chemical entity, selective androgen receptor agonist that targets and activates the androgen receptor, a tumor suppressor, to treat AR+ER+HER2- metastatic breast cancer without unwanted masculinizing side effects; Phase 3 ARTEST clinical trial to evaluate enobosarm in approximately 210 subjects with AR+ER+HER2- advanced breast cancer who have failed nonsteroidal aromatase inhibitor, fulvestrant, and a CDK 4/6 inhibitor is anticipated to commence Q2 2021. The second indication for VERU-111 is for the treatment of taxane resistant metastatic triple negative breast cancer; the planned Phase 2b in 200 subjects is expected to begin Q3 2021. Based on positive Phase 2 results on the reduction of mortality, VERU-111 is being evaluated in a Phase 3 trial in 300 subjects for the treatment of hospitalized patients with COVID-19 who are at high risk for acute respiratory distress syndrome. The Company’s Sexual Health Business commercial product is the FC2 Female Condom® (internal condom) (“FC2”), an FDA-approved product for dual protection against unintended pregnancy and the transmission of sexually transmitted infections. The Company’s Female Health Company Division markets and sells FC2 commercially and in the public health sector both in the U.S. and globally. In the U.S., FC2 is available by prescription through multiple third-party telemedicine and internet pharmacy providers and retail pharmacies. In the global public health sector, the Company markets FC2 to entities, including ministries of health, government health agencies, U.N. agencies, nonprofit organizations and commercial partners, that work to support and improve the lives, health and well-being of women around the world. The second product expected for the Sexual Health Business is TADFIN™ (tadalafil 5mg and finasteride 5mg) capsule for the administration of tadalafil 5mg and finasteride 5mg combination formulation dosed daily for benign prostatic hyperplasia (BPH). An NDA was submitted in February 2021. To learn more about Veru products, please visit www.verupharma.com. "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: The statements in this release that are not historical facts are "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this release include statements regarding the potential of enobosarm to treat certain breast cancer patients and whether future clinical development will demonstrate sufficient efficacy and safety to secure FDA approval of the Company's drug candidates and statements regarding the expected timing, design and efficacy of the other drug candidates in the Company's development pipeline. Any forward-looking statements in this release are based upon the Company's current plans and strategies and reflect the Company's current assessment of the risks and uncertainties related to its business and are made as of the date of this release. The Company assumes no obligation to update any forward-looking statements contained in this release because of new information or future events, developments or circumstances. Such forward-looking statements are subject to known and unknown risks, uncertainties and assumptions. If any such risks or uncertainties materialize or if any of the assumptions prove incorrect, our actual results could differ materially from those expressed or implied by such statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to, the following: risks related to the development of the Company's product portfolio, including clinical trials, regulatory approvals and the time and cost to bring any of our product candidates to market; potential delays in the timing of and results from clinical trials and studies, including potential delays in the recruitment of patients and their ability to effectively participate in such trials and studies due to COVID-19, and the risk that such results will not support marketing approval and commercialization; potential delays in the timing of any submission to the FDA and regulatory approval of products under development and the risk that disruptions at the FDA caused by the COVID-19 pandemic may delay the review of submissions or approvals for new drugs; the risk of a delay or failure in reaching agreement with the FDA on the design of a clinical trial or in obtaining authorization to commence a clinical trial; preclinical or clinical results or early data from clinical trials may not be replicated or continue to occur in additional trials or may not otherwise support further development in the specified product candidate or at all; our pursuit of a COVID-19 treatment candidate is at an early stage and we may be unable to develop a drug that successfully treats the virus in a timely manner, if at all; risks related to our commitment of financial resources and personnel to the development of a COVID-19 treatment which may cause delays in or otherwise negatively impact our other development programs, despite uncertainties about the longevity and extent of COVID-19 as a global health concern and the possibility that as vaccines become widely distributed the need for new COVID-19 treatment candidates may be reduced or eliminated; government entities may take actions that directly or indirectly have the effect of limiting opportunities for VERU-111 as a COVID-19 treatment, including favoring other treatment alternatives or imposing price controls on COVID-19 treatments; the risk that the Company's existing products and any future products, if approved, may not be commercially successful; risks related to the impact of the COVID-19 pandemic on our business, the nature and extent of which is highly uncertain and unpredictable; risks relating to the ability of the Company to obtain sufficient financing on acceptable terms when needed to fund development and operations, including our ability to secure timely grant or other funding to develop VERU-111 as a potential COVID-19 treatment; product demand and market acceptance; competition in the Company's markets and therapeutic areas and the risk of new or existing competitors with greater resources and capabilities and new competitive product approvals and/or introductions; the risk that the Company will be affected by regulatory developments, including a reclassification of products; price erosion, both from competing products and increased government pricing pressures; manufacturing and quality control problems; compliance and regulatory matters, including costs and delays resulting from extensive governmental regulation, and effects of healthcare insurance and regulation, including reductions in reimbursement and coverage or reclassification of products; some of the Company's product candidates are in development and the Company may fail to successfully commercialize such products, if approved; risks related to intellectual property, including the uncertainty of obtaining patents, the effectiveness of the patents or other intellectual property protections and ability to enforce them against third parties, the uncertainty regarding patent coverages, the possibility of infringing a third party’s patents or other intellectual property rights, and licensing risks; government contracting risks, including the appropriations process and funding priorities, potential bureaucratic delays in awarding contracts, process errors, politics or other pressures, and the risk that government tenders and contracts may be subject to cancellation, delay, restructuring or substantial delayed payments; the risk that delays in orders or shipments under government tenders or the Company’s U.S. prescription business could cause significant quarter-to-quarter variations in the Company’s operating results and adversely affect its net revenues and gross profit; a governmental tender award indicates acceptance of the bidder's price rather than an order or guarantee of the purchase of any minimum number of units, and as a result government ministries or other public sector customers may order and purchase fewer units than the full maximum tender amount or award; penalties and/or debarment for failure to satisfy tender awards; the Company's reliance on its international partners and on the level of spending by country governments, global donors and other public health organizations in the global public sector; risks related to concentration of accounts receivable with our largest customers and the collection of those receivables; the economic and business environment and the impact of government pressures; risks involved in doing business on an international level, including currency risks, regulatory requirements, political risks, export restrictions and other trade barriers; the Company's production capacity, efficiency and supply constraints and interruptions, including potential disruption of production at the Company’s and third party manufacturing facilities and/or of the Company’s ability to timely supply product due to labor unrest or strikes, labor shortages, raw material shortages, physical damage to the Company’s and third party facilities, COVID-19 (including the impact of COVID-19 on suppliers of key raw materials), product testing, transportation delays or regulatory actions; risks related to the costs and other effects of litigation, including product liability claims; the Company's ability to identify, successfully negotiate and complete suitable acquisitions or other strategic initiatives; the Company's ability to successfully integrate acquired businesses, technologies or products; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings, including the Company's Form 10-K for the fiscal year ended September 30, 2020 and subsequent quarterly reports on Form 10-Q. These documents are available on the "SEC Filings" section of our website at www.verupharma.com/investors. Contact:Sam Fisch 800-972-0538Director of Investor Relations

  • Is Veru Inc.'s (NASDAQ:VERU) Stock Price Struggling As A Result Of Its Mixed Financials?
    Simply Wall St.

    Is Veru Inc.'s (NASDAQ:VERU) Stock Price Struggling As A Result Of Its Mixed Financials?

    It is hard to get excited after looking at Veru's (NASDAQ:VERU) recent performance, when its stock has declined 37...

  • 2 “Strong Buy” Stocks Around $10 With Triple-Digit Upside Potential
    TipRanks

    2 “Strong Buy” Stocks Around $10 With Triple-Digit Upside Potential

    The S&P 500 rose to another record high on Friday, and at least one strategist believes we’re at the start of a new bull market. Writing from LPL Financial, chief market strategist Ryan Detrick noted several market-historical points that indicate sustained gains are in the offing. Key among his points are the first quarter returns and the breadth of the current stock rally. On returns, Detrick highlights that the S&P 500 gained nearly 6% in Q1 – and that the 6% level has been an accurate indicator for near-term trends. “Since 1950, when the S&P 500 was up between 5% and 10% in the first quarter, the rest of the year gained another 12.4% on average and was higher 86.7% of the time," the strategist noted. The breadth of the gains may be a more important point, however. Detrick tells us that the current rally is attracting participation from a range of different market sectors – stocks are up nearly across the board, with 95% of the S&P 500 components pushing above their 200 day moving average in recent weeks. Detrick shows that this pattern was prevalent in December 2003 and September 2009 – and that those two months marked the start of years-long bull runs. So the key now, to thriving in the coming environment, is to find stocks that are primed for gains. Using the TipRanks database, we’ve found two stocks that fit a profile: they boast a Strong Buy analyst consensus rating, trading prices around $10 per share, and best of all, they could bring massive growth prospects to the table. We’re talking about triple-digit upside potential here. F-star Therapeutics (FSTX) First up is F-star Therapeutics, a clinical stage biopharma company with a focus on immune-oncology. The company’s pipeline features tetravalent mAb2 bispecific antibodies, a proprietary technology which F-star believes will meet the challenges of immune-oncology therapies. According to the company, the antibodies are ‘designed to address multiple immune evasion pathways,’ thereby enhancing their effect over currently available therapies. F-star has a development pipeline featuring both proprietary and partnership programs. FS118, the most advanced drug candidate, has completed a Phase 1 clinical trial, which showed positive results, with signs of clinical activity related to its novel mechanism of action. A proof-of-concept trial is now underway, with patients suffering from PD-1 resistant head and neck cancers. In addition, the European Patent Office in January of this year granted a patent on the FS118 molecule, with an expiry date in 2037. The next most advanced program, FS222, is described as a ‘potentially best-in-class bispecific antibody targeting CD137 and PD-L1.’ The drug candidate is starting a Phase 1 trial, with the first patient dosed this past January. The trial will evaluate safety, tolerability, and early signs of efficacy. The patient base will be adults, with a diagnosis of advanced malignancies. This past November, F-star went public on the NASDAQ through a SPAC merger. The merger was completed, and the FSTX ticker started trading, on November 23; since then, the stock has gained an impressive 151%. Describing the company as "a potential north star of bispecific antibody engineering," Oppenheimer’s 5-star analyst Hartaj Singh believes that there is plenty of upside left for FSTX. “We believe FSTX screens well among various bispecific antibody (BsAbs) platforms evolving rapidly in the past two years (our white paper), given the company platform's ability to leverage the three key features of BsAbs: conditionality/ crosslinking/clustering through its molecules' Fc-gamma receptor (FcγR) independent tetravalent binding and generate uncorrelated high-value oncology assets," Singh opined. The analyst, added, "In our opinion, FSTX's story has checked the boxes for: (1) a biomarker-driven targeted oncology approach identifying a patient population subset that allows accelerated approval; (2) enhanced risk/benefit profile with low immunogenicity/high-affinity target engagement/no hook effect/etc.; (3) unveiling novel target synergy unattainable by mAbs combination; and (4) experienced/execution-focused management." In line with his bullish view, Sing rates FSTX an Outperform (i.e. Buy), and sets a $30 price target. His target implies a 200% one-year upside potential. (To watch Singh’s track record, click here) Singh is no outlier on this one. The four most recent reviews on F-star are to "buy," making the analyst consensus rating a Strong Buy. The shares are trading for $9.98, and their $33.5 average price target suggests a 235% upside for the year ahead. (See FSTX stock analysis on TipRanks) Veru (VERU) Veru, the next company we’re looking at, is another biopharma company with an oncology focus. The company is working on new medical treatments for prostate and breast cancer, two malignancies that have a high profile. Veru’s lead pipeline candidate, VERU-111, is under investigation as a treatment for both prostate cancer and breast cancer, and is even undergoing testing as a potential treatment for COVID-19. The drug candidate has started a Phase 2 clinical trial in the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer. The trial is fully enrolled and ongoing, and no severe adverse effects have been reported. Efficacy results include PSA declines along with objective, lasting tumor responses. The second application of VERU-111 is in the treatment of metastatic triple negative breast cancer (TNBC), and aggressive form of the disease that makes up some 15% of all breast cancer cases. TNBC patients could be candidates for treatment with VERU-111, and preclinical studies have shown that the drug candidate can significantly inhibit the proliferation, migration, metastases, and invasion of TNBC tumor cells that have developed resistance to taxane treatment. Veru will be meeting with the FDA during 1H21 to discuss trial designs for a Phase 2b clinical study of this medical avenue, to be commenced in 2H21. VERU-111 has also completed an expedited Phase 2 clinical study of its efficacy for treating patients hospitalized with COVID-19 and at high risk for Acute Respiratory Distress Syndrome (ARDS). The FDA has agreed to advance the study to a Phase 3 trial, to confirm the risk/benefit analysis. Clinical results are expected to start coming in during 4Q21. Another drug the company had been developing for the treatment of breast cancer is enobosarm, a selective androgen receptor agonist, which could potentially treat AR+/HR+ breast cancers resistant to current endocrine therapy. The company plans to start a Phase 3 study for enobosarm in coming months, with data expected in 2H23. In addition, the company has submitted its NDA for tadalafil, a new drug for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. The PDUFA date is expected in December 2021, and if approved, Veru will market the drug through third-party telemedicine partners. The company also has an FDA-approved product, FC2, a female, internal condom for the prevention of unintended pregnancies as well as disease prevention. During the fourth quarter, the company saw a 50% growth in prescription sales of FC2, with revenues climbing to $9.1 million from $6.1 million in 4Q20. The multi-applications have attracted attention from Jeffries analyst Chris Howerton, who rates VERU shares a Buy along with a $19 price target. This figure suggests 104% upside potential from the current share price of $9.32. (To watch Howerton’s track record, click here) “We like lead oncology programs, '111 for prostate cancer and enobasarm for breast cancer, which will enter Ph3 imminently, positive results from which could unlock cumulative, peak, unadjusted sales of >$3B. After recent strategy shift, non-core/legacy assets are expected to be divested, which could provide NT, non-dilutive capital," Howerton noted. The analyst continued, "We view other, non-core pipeline programs and business units, such as their female condom (FC2), as call options to our fundamental valuation. Historically, Veru was built as a prostate-focused company, w/ a supportive sexual health business to 'pay the bills.' As a result, there are idiosyncratic features of their pipeline that could provide incremental, near-to-medium term upside, but we do not see as material to long-term valuation." The rest of Wall Street echoes Howerton’s bullish play, as TipRanks analytics exhibit VERU as a Strong Buy. Out of 5 analysts tracked in the last 3 months, all 5 are bullish on the stock. With a return potential of ~154%, the stock’s consensus price target stands at $23.60. (See VERU stock analysis on TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.